COMMUNIQUÉS West-GlobeNewswire

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
23/12/2025
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of [...]
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
23/12/2025
Milestone advances manufacturing readiness and supports long-term commercialization strategy BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: [...]
Cassava Announces Agreement to Settle Securities Class Action Litigation
23/12/2025
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous [...]
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
23/12/2025
Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) [...]
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
23/12/2025
Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of [...]
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
23/12/2025
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based [...]
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
23/12/2025
PYLCLARI ® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, has announced that [...]
CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
23/12/2025
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific Leadership Lehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, December 23, 2025 - CancerVax, Inc., the [...]
Burning Rock Announces Results of 2025 Annual General Meeting
23/12/2025
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “ Company ” or “ Burning Rock ”), a company focusing on the application of next generation sequencing (NGS) technology [...]
Vireo Growth Inc. Enters California and Florida and Strengthens Delivery Platforms with Acquisition of Eaze Inc.
23/12/2025
Transaction will expand Vireo’s operating footprint to 10 states with 166 dispensaries and approximately 800,000 sq. ft. of cultivation and production Acquisition also will add an incremental 14 dispensaries to Company’ [...]
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
23/12/2025
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first [...]
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique
23/12/2025
Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
23/12/2025
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by [...]
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-Year NEW [...]
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
22/12/2025
FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene [...]
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The [...]
Apollomics Reports First Half 2025 Financial Results
22/12/2025
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025
Wegovy ® pill showed a mean weight loss of 16.6% in the OASIS 4 trial 1 Wegovy ® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse [...]

Pages